Current Oncology, Vol. 30, Pages 5337-5349: Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review

Current Oncology, Vol. 30, Pages 5337-5349: Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review

Current Oncology doi: 10.3390/curroncol30060405

Authors: Yingying Jiang Xiaoxu Fang Yan Xiang Tingwen Fang Jingwen Liu Kaihua Lu

Afatinib, the world’s first irreversible ErbB family (containing four different cancer cell epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a second-generation oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). It can be used as a first-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) with an EGFR-sensitive mutation or for patients with locally advanced or metastatic squamous lung cancer whose disease progresses during or after platinum-containing chemotherapy. Currently, with the use of third-generation EGFR-TKIs, afatinib is no longer clinically indicated as the first choice for patients with NSCLC who have EGFR-sensitive mutations. However, afatinib showed a considerable inhibitory effect in NSCLC patients with uncommon EGFR mutations (G719X, S768I, and L861Q) according to a combined post hoc analysis of the LUX-Lung2/3/6 trials. With the development of genetic testing technology, the detection rate of uncommon EGFR mutations is increasing. The aim of this paper is to describe in detail the sensitivity of rare EGFR mutations to afatinib and to provide information and a reference for those suffering from advanced NSCLC who have uncommon EGFR mutations.